SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 1 of 7
		No.: FPS: G13
	FINISHED PRODUCT SPECIFICATION	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

01	GENERAL	Pharmacopoeia Reference	BP
02	Composition	Label Claim	
	Each film coated tablet contains:		
	Cetirizine Hydrochloride BP	10 mg	
03	Shelf life	36 months	
04	Quantity of sample taken for analysis	Lubricated granules: 100 gm Bulk sample: 120'S (For complete analysis) Finished product: 12 X 10'S (For Physical parameter & Microbiological Limit Test only)	
05	Control sample	7 [3 X 10'S]	
06	Storage of Finished pack	Store in cool and dry place. Protect from light and moisture.	

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

MASTER COPY

UNCONTROLLED COPY

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 2 of 7
		No.: FPS: G13
	FINISHED PRODUCT SPECIFICATION	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

BULK GRANULES SPECIFICATION

S.No.	TEST	LIMIT	METHOD
01	DESCRIPTION	White coloured granular powder.	Follow section I of Method of analysis
02	ASSAY (By HPLC)		Follow section XII of Method of analysis
	Each 118 mg Granules Contains:		
	Cetirizine Hydrochloride BP-10 mg	Not less than 95.0% and Not more than 105.0%	

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

MASTER COPY

UNCONTROLLED COPY

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 3 of 7 No.: FPS: G13
	FINISHED PRODUCT SPECIFICATION	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

BULK PRODUCT SPECIFICATION

S.No.	TEST	LIMIT	METHOD
01	DESCRIPTION	White coloured, caplet shaped, uncoated tablet with break line on one side and plain on other side.	Follow section I of Method of analysis
02	AVERAGE WEIGHT	118.00 mg ± 5.0% (Limit: 112.10 mg to 123.90 mg)	Follow section III of Method of analysis
03	UNIFORMITY OF WEIGHT	NMT 2 tablets deviate by more than ± 7.5 % and none deviates by more than ± 15.0 % from the average weight.	Follow section IV of Method of analysis
04	DIMENSIONS Thickness Length Width	 2.40 mm to 3.00 mm 9.80 mm to 10.20 mm 3.80 mm to 4.20 mm	Follow section V of Method of analysis
05	HARDNESS	NLT 2 Kg/cm^2	Follow section VI of Method of analysis
06	FRIABILITY	NMT 1.0 %	Follow section VII of Method of analysis
07	DISINTEGRATION TIME	Not more than 15 minutes	Follow section VIII of Method of analysis
08	DISSOLUTION By UV Cetirizine Hydrochloride BP-10 mg	 Not less than 85.0 % of labeled amount	Follow section X of Method of analysis
09	ASSAY (By HPLC) **Each Uncoated tablet contains:** Cetirizine Hydrochloride BP-10 mg	 Not less than 95.0% and Not more than 105.0%	Follow section XII of Method of analysis

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

MASTER COPY

UNCONTROLLED COPY

SAI.PRIMUS LIFE BIOTECH (P) LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 4 of 7 No.: FPS: G13
	FINISHED PRODUCT SPECIFICATION	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

RELEASE SPECIFICATION

S.No.	TEST	LIMIT	METHOD
01	DESCRIPTION	White coloured, caplet shaped, film coated tablet with break line on one side and plain on other side.	Follow section I of Method of analysis
02	IDENTIFICATION By IR	The infrared absorption spectrum of the residue is concordant with the reference spectrum of cetirizine hydrochloride.	Follow section II of Method of analysis
03	AVERAGE WEIGHT	120.00 mg ± 5.0% (Limit: 114.00 mg to 126.00 mg)	Follow section III of Method of analysis
04	UNIFORMITY OF WEIGHT	NMT 2 tablets deviate by more than ± 7.5 % and none deviates by more than ± 15.0 % from the average weight.	Follow section IV of Method of analysis
05	DIMENSIONS		Follow section V of Method of analysis
	Thickness	2.50 mm to 3.10 mm	
	Length	10.0 mm to 10.40 mm	
	Width	4.00 mm to 4.40 mm	
06	HARDNESS	NLT 2 Kg/cm^2	Follow section VI of Method of analysis
07	DISINTEGRATION TIME	Not more than 30 minutes	Follow section VIII of Method of analysis
08	CONTENT UNIFORMITY By HPLC		Follow section IX of Method of analysis
	Cetirizine Hydrochloride BP-10 mg	NLT 85.0 % and NMT 115.0 % of labeled claim	
09	DISSOLUTION By UV		Follow section X of Method of analysis
	Cetirizine Hydrochloride BP-10 mg	Not less than 85.0 % of labeled amount	
10	RELATED SUBSTANCES By HPLC		Follow section XI of Method of analysis
	Impurity A	Not more than 0.3 %	
	Impurity B	Not more than 0.3 %	
	Impurity G	Not more than 0.3 %	
	Single maximum unknown impurity	Not more than 0.2 %	
	Total impurities	Not more than 1.0 %	

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature	M.M.+	J.kanp	
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

MASTER COPY

UNCONTROLLED COPY

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 5 of 7 No.: FPS: G13
	FINISHED PRODUCT SPECIFICATION	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

S.No.	TEST	LIMIT	METHOD
11	ASSAY (By HPLC) **Each film coated tablet contains:** Cetirizine Hydrochloride BP-10 mg	Not less than 95.0% and Not more than 105.0%	Follow section XII of Method of analysis
12	**MICROBIOLOGICAL LIMITS**		Follow section XIII of Method of analysis
	Total Aerobic Microbial count	NMT 1000 CFU/g	
	Total Yeasts and mould counts	NMT 100 CFU/g	
	E. coli	Should be Absent/g	
	Salmonella	Should be Absent/10g	
	S. aureus	Should be Absent/g	
	P. aeruginosa	Should be Absent/g	

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

SAI PRIMUS LIFE BIOTECH PVT. LTD.	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 6 of 7 No.: FPS: G13
	FINISHED PRODUCT SPECIFICATION	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

SHELF LIFE SPECIFICATION

S.No.	TEST	LIMIT	METHOD
01	**DESCRIPTION**	White coloured, caplet shaped, film coated tablet with break line on one side and plain on other side.	Follow section I of Method of analysis
02	**AVERAGE WEIGHT**	120.00 mg ± 5.0% (Limit: 114.00 mg to 126.00 mg)	Follow section III of Method of analysis
03	**HARDNESS**	NLT 2 Kg/cm^2	Follow section VI of Method of analysis
04	**DISINTEGRATION TIME**	Not more than 30 minutes	Follow section VIII of Method of analysis
05	**DISSOLUTION By UV** Cetirizine Hydrochloride BP-10 mg	Not less than 85.0 % of labeled amount	Follow section X of Method of analysis
06	**RELATED SUBSTANCES By HPLC**		Follow section XI of Method of analysis
	Impurity A	Not more than 0.3 %	
	Impurity B	Not more than 0.3 %	
	Impurity G	Not more than 0.3 %	
	Single maximum unknown impurity	Not more than 0.2 %	
	Total impurities	Not more than 1.0 %	
07	**ASSAY (By HPLC)** **Each film coated tablet contains:** Cetirizine Hydrochloride BP-10 mg	Not less than 95.0% and Not more than 105.0%	Follow section XII of Method of analysis
08	**MICROBIOLOGICAL LIMITS**		Follow section XIII of Method of analysis
	Total Aerobic Microbial count	NMT 1000 CFU/g	
	Total Yeasts and mould counts	NMT 100 CFU/g	
	E.Coli	Should be Absent/g	
	Salmonella	Should be Absent/10g	
	S.aureus	Should be Absent/g	
	P.aeruginosa	Should be Absent/g	

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

MASTER COPY

UNCONTROLLED COPY

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 7 of 7
		No.: FPS: G13
	FINISHED PRODUCT SPECIFICATION	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

HISTORY

S. No.	Revision Number	Reason for Revision
1	Revision No.: 00	New Specification No: G13
2	Revision No.: 01	Periodic Revision
3	Revision No.: 02	Revision reference to the change control CC/24/034.
4	Revision No.: 03	Revision reference to the change control CC/24/087
5	Revision No.: 04	Revision reference to the change control CC/25/051

END OF DOCUMENT

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

MASTER COPY

UNCONTROLLED COPY

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 1 of 12
		No.: FPSTP: G13
	FINISHED PRODUCT STANDARD TEST PROCEDURE	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

METHOD OF ANALYSIS

SECTION – I

DESCRIPTION: (By Visual Inspection)

Check physical aspects – Colour, shape and nature of tablets, presence of foreign material, mottling etc.,

SECTION – II

IDENTIFICATION By IR

Shake a quantity of the powdered tablets containing 50 mg of Cetirizine Hydrochloride with 20 mL of absolute ethanol, filter (Whatman GF/C is suitable), evaporate the filtrate and dry the residue at 60° for 1 hour. The infrared absorption spectrum of the residue.

SECTION – III

AVERAGE WEIGHT

Weigh 20 tablets and note down weight in g. Determine the average weight.

Report the result of average weight in mg.

$$\text{Average weight} = \frac{\text{Weight of 20 tablets in g}}{20} \times 1000 = \_\_\_\_\_ \text{ mg}$$

SECTION – IV

UNIFORMITY OF WEIGHT

Weigh individually 20 tablets taken for average weight. Calculate the percentage of highest and lowest variation of the tablets with maximum and minimum weight from the average weight of tablets by the following expression.

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 2 of 12
	FINISHED PRODUCT STANDARD TEST PROCEDURE	No.: FPSTP: G13
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Revision No: 04
	Product Code: G13	Review Period: 3 Years
		Effective Date: 04/03/2025

Calculation:

$$\left(\frac{\text{Lowest Wt. of Tablet}}{\text{Avg. Wt. of Tablet}} \times 100 \right) - 100 = -\,\%$$

$$\left(\frac{\text{Highest Wt. of Tablet}}{\text{Avg. Wt. of Tablet}} \times 100 \right) - 100 = +\,\%$$

SECTION – V

DIMENSIONS

Measure the Thickness, Length & Width of 10 tablets using Digital Vernier Calipers. Record the reading in mm.

SECTION – VI

HARDNESS

Take 10 tablets randomly from sample drawn for analysis. Place one tablet diagonally in between the space provided in the hardness tester. Operate the instrument for tablet hardness tester. Note down the reading when tablet breaks. Repeat the test for remaining 9 tablets and record the values in kg/cm^2. Express the results as the minimum and maximum values in kg/cm^2.

SECTION – VII

FRIABILITY

Weigh accurately about 6.5 g of tablets note down the mass in grams (a). Place weighed tablets in friability test apparatus and operate the instrument as per SOP for tablet friability test apparatus, for 100 rotations. After completion of test collect the tablets from the sample collector carefully. Remove broken particles, chipped pieces (if any) by means of gentle brushing. Weigh the tablet and record the mass in grams (b).

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature	M.M+	J. temp	
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

Calculate the weight loss (c= a-b).

Calculate the percentage as follows:

Calculation

$\frac{c \times 100}{a} =$ % w/w

SECTION – VIII

DISINTEGRATION TIME

Determine on 6 tablets using water at 37°C ± 2°C.Place one tablet each in six tubes of the disintegration test apparatus, add a disc and suspend the assembly in water maintained at 37 ± 2°C.Operate the apparatus till all residue passes through the mesh and note down the time taken. The time taken should not be more than the limit indicated in the product specification. If the tablets adhere to the disc repeat the test omitting the disc.

SECTION – IX

ASSAY AND CONTENT UNIFORMITY By HPLC

Chromatographic Condition:

Column	:	C18, 250 mm × 4.6 mm, packed with octadecyl silyl silica gel (5 µm) (Phenomenex Luna C18 (2) column is suitable) or equivalent
Flow rate	:	1.0 mL/min
Wavelength	:	230 nm
Injection volume	:	20 µL
Column Oven Temperature	:	30°C

SAI PRIMUS LIFE	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 4 of 12
	FINISHED PRODUCT STANDARD TEST PROCEDURE	No.: FPSTP: G13
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Revision No: 04
	Product Code: G13	Review Period: 3 Years
		Effective Date: 04/03/2025

Preparation of Buffer Solution:

Weight accurately 0.34 gm of Potassium Dihydrogen Orthophosphate into 1000 mL of water. Sonicate to dissolve and adjust to pH 1.5 ± 0.05 with Orthophosphoric acid.

Preparation of Mobile Phase:

Mix 700 mL of Buffer Solution and 300 mL of Acetonitrile. Filter through 0.45-micron membrane filter and degas.

Preparation of Solution-3:

Weight accurately about 2 mg of Impurity standard BPCRS and transfer into a 10 mL volumetric flask. Add about 5 mL of mobile phase, sonicate with intermediate shaking to dissolve and dilute up to the volume with mobile phase. (Concentration: 0.2 mg/mL)

Preparation of Solution-2:

Weight Accurately and transfer about 20 mg of Cetirizine hydrochloride working standard into 100 mL volumetric flask. Add about 50 mL of mobile phase, sonicate with intermediate shaking to dissolve and dilute up to the volume with mobile phase. Further dilute 10 mL of this solution to 100 mL with mobile phase. (Conc.0.02 mg/mL)

Preparation of Solution-1 Sample Powder:

Weigh accurately 20 tablets and make the powder using mortar and pestle. Use the same for preparation of sample solution. Calculate the average weight by taking weight of 20 tablets taken above and use the same for calculation.

Preparation of Solution-1:

Weight accurately and transfer about 240 mg of powdered sample (equivalent to 20 mg Cetirizine hydrochloride) into 100 mL volumetric flask. Add about 70 mL of mobile phase, shake for 15 minutes with to dissolve, cool and dilute up to the volume with mobile phase. Filter sufficient quantity of this solution through 0.45µm nylon syringe filter and inject. Further dilute 10 mL of this solution to 100 mL with mobile phase and inject.

Note: Prepare sample solution in duplicate.

Preparation of Sample solution CU:

Weigh 10 random tablets individually and transfer them into ten 100 mL volumetric flask containing 10 mL of

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature	H.M.T	J. Kamal	
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

water. Keep as it is until the complete dispersion of tablets. Add 50 mL of mobile phase, sonicate for 10 minutes with intermediate shaking and dilute up to the volume with mobile phase. Filter sufficient quantity of this solution through 0.45μ nylon syringe filter and further dilute 5 mL of this solution to 25 mL with mobile phase.

Procedure:

Equilibrate the chromatographic system with mobile phase till a stable baseline is obtained. Separately inject equal volumes (20 μL) of solutions as per Sequence of injections into the chromatograph and record the peak area responses for the major peaks and check for the System suitability requirements.

Sequence of Injections:

S. No	Solution type	No. of injections
1.	Blank	1
2.	Solution 3	1
3.	Solution 2	5
4.	Solution 1-1	1
5.	Solution 1-2	1
6.	Bracketing Solution 2 - 1	1
7.	Content Uniformity solution 1-5	1
8.	Bracketing Solution 2 - 2	1
9.	Content Uniformity solution 6-10	1
10.	Bracketing Solution 2 - 2	1

Note: Bracketing standards may vary as per In-House SOP.

System suitability requirement:

1. The Resolution between the peaks of Cetirizine hydrochloride and Impurity B obtained with impurity standard solution should not less than 1.5.
2. The tailing factor for the peak of Cetirizine hydrochloride obtained with standard solution should not more than 2.0:

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature	[signature]	[signature]	[signature]
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

MASTER COPY	UNCONTROLLED COPY

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 6 of 12
		No.: FPSTP: G13
	FINISHED PRODUCT STANDARD TEST PROCEDURE	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

3. The column efficiency for the peak of Cetirizine hydrochloride obtained in the chromatogram of standard solution should not less than 2000.
4. The % RSD for the peak area response of Cetirizine Hydrochloride peak obtained with the replicate injections of standard solution should not more than 2.0.
5. The % RSD for the peak area response of Cetirizine Hydrochloride peak obtained with the replicate injections of standard solution and bracketing standard solution should not more than 2.0.

Calculation: (% Assay)

1) Calculate the content of Cetirizine Hydrochloride by using following formula,

$$= \frac{A}{B} \times \frac{W1}{100} \times \frac{10}{100} \times \frac{100}{W2} \times \frac{100}{10} \times \frac{Av}{LC} \times \frac{P}{100} \times 100$$

2) Calculation: (% Content / Tab):

$$= \frac{A}{B} \times \frac{W1}{100} \times \frac{10}{100} \times \frac{100}{1} \times \frac{25}{5} \times \frac{P}{100} \times \frac{100}{LC}$$

Were,

A = Peak area response of Cetirizine hydrochloride peak obtained from the sample solution

B = Average peak area response of Cetirizine hydrochloride peak obtained with replicate injection standard Solution

W1 = Weight of Cetirizine hydrochloride working standard in mg

W2 = Weight of sample in mg

Av = Average weight of sample in mg

LC = Label claim

P = Purity of Cetirizine hydrochloride working standard on as is basis in %

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature	M.M+	J-kumar	AP
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 7 of 12
		No.: FPSTP: G13
	FINISHED PRODUCT STANDARD TEST PROCEDURE	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

SECTION – X

DISSOLUTION (By UV):

Dissolution Parameters:

Medium	:	Water
Volume	:	900 mL
Apparatus	:	Apparatus Type II (Paddle)
RPM	:	50
Temperature	:	37°C
Time	:	45 minutes

Preparation of Solution-2:

Weight Accurately and transfer about 25 mg of Cetirizine hydrochloride working standard into a 100 mL volumetric flask. Add about 20 mL of water, sonicate to dissolve and dilute up to the mark with water. Further dilute 2 mL of this solution to 100 mL with water. (Conc.0.0050 mg/mL)

Preparation of Solution-1:

Place the stated volume of dissolution medium in each vessel of the dissolution apparatus. Equilibrate the dissolution medium at 37°C ± 0.5°C. Transfer 1 tablet in to each vessel. Immediately operate the apparatus at specified speed. At the end of specified time interval, withdraw 10 mL of aliquot from each specimen. Filter through 0.45µ nylon syringe filter. Dilute 5 mL of this solution to 10 mL with dissolution medium.

(Conc.0.0056 mg/mL)

(Aliquot withdrawal Position: - from the midway zone between the top surface of dissolution medium and top of rotating paddle and 1 cm away from vessel wall.)

Note: Carry out dissolution test on six tablets.

Instrument parameters for US-Vis Spectrophotometer:

Detection wavelength: 230 nm and 260 nm

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

MASTER COPY

UNCONTROLLED COPY

Path length: 1 cm

Cuvette: Quartz

Procedure:

Measure the absorbance of Standard and sample solution in water at the maximum wavelengths at 230 nm and 260 nm using dissolution medium in reference cell and calculate the difference between two readings (Δ A) for each measurement.

Calculation:

Calculate the content of Cetirizine hydrochloride by using following formula,

$$\text{\% Dissolution} = \frac{Au}{As} \times \frac{Ws}{100} \times \frac{2}{100} \times \frac{900}{LC} \times \frac{10}{5} \times P$$

Were,

Au = Absorbance of Cetirizine hydrochloride obtained from sample solution.

As = Average absorbance of Cetirizine hydrochloride BPCRS obtained from standard solution.

Ws = Weight of Cetirizine hydrochloride working standard in mg.

LC = Label claim

P = % Potency of Cetirizine hydrochloride on as is basis.

SECTION – XI

RELATED SUBSTANCES (By HPLC):

Chromatographic Condition:

Column type	:	C18, 250 mm × 4.6 mm, packed with octadecyl silyl silica gel (5 µm) (Phenomenex Luna C18 (2) column is suitable) or equivalent
Flow rate	:	1.0 mL / minute

Detector wavelength	:	230 nm
Column oven temperature	:	30 °C
Injection volume	:	20 µL
Diluent	:	Mobile phase-A

Preparation of Mobile Phase-A:

Mix 170 mL of Acetonitrile and 830 mL of water previously adjusted pH to 1.5 ± 0.05 with orthophosphoric acid. Filter and Degas.

Preparation of Mobile phase-B:

Mix 350 mL of Acetonitrile and 650 mL of water previously adjusted pH to 1.5 ± 0.05 with orthophosphoric acid. Filter and Degas.

Gradient Program:

Time (mins)	Mobile phase A	Mobile phase B	Comment
0 - 50	100 → 0	0 → 100	Linear gradient
50 - 53	0	100	Isocratic
53 - 54	0 →100	100 →0	Linear gradient
54 - 60	100	0	Re - equilibration

Preparation of Placebo solution:

Weight accurately and transfer about 220mg of placebo (equivalent to 20 mg Cetirizine hydrochloride) into 20 mL volumetric flask. Add about 10 mL of diluent, shake for dissolve and dilute up to the volume with diluent. Filter sufficient quantity of this solution through 0.45µ nylon filter.

Preparation of solution-4:

Weight accurately about 2 mg of Impurity standard BPCRS and transfer into a 10 mL volumetric flask. Add about 5 mL of diluent, sonicate with intermediate shaking to dissolve and dilute up to the volume with diluent. (Concentration: 0.2 mg/mL)

Preparation of Solution-2:

Dilute 1 mL of solution-1 in to 100 mL with diluent. Further dilute 10 mL of this solution to 50 mL of with diluent. (Concentration:0.002 mg/mL)

Preparation of Solution-3:

Dilute 5 mL of solution-2 to 10 mL with diluent. (concentration:0.001 mg/mL).

Preparation of Solution-1:

Take accurately 20 tablets and triturate to fine powder with mortar & pestle. Weight accurately and transfer 240 mg of sample powder (equivalent to 20 mg Cetirizine hydrochloride) into 20 mL of volumetric flask. Add about 10 mL of diluent, shake for dissolve and dilute up to the volume with diluent. Filter sufficient quantity of this solution through 0.45µm nylon syringe filter.

Procedure:

Equilibrate the chromatographic system with mobile phase till a stable baseline is obtained. Separately inject equal volumes (20 µl) of solutions as per Sequence of injections into the chromatograph and record the peak area responses for the major peaks and check for the System suitability requirements.

Sequence of injection:

S. No.	Solution type	No. of injections
1.	Blank	1
2.	Placebo	1
3.	Blank	1
4.	Solution-4	1
5.	Blank	1
6.	Solution-1	1
7.	Solution-2	1
8.	Solution-3	1
9.	Blank	1

SAI PRIMUS LIFE BIOTECH PVT LTD	SAI PRIMUS LIFE BIOTECH PVT LTD Factory: R.S. No. 4/3, Plot No.33, Kurumbapet Industrial Estate, Villianur Commune, Puducherry-605009	Page 11 of 12
		No.: FPSTP: G13
	FINISHED PRODUCT STANDARD TEST PROCEDURE	Revision No: 04
Title:	GENSET TABLETS (Cetirizine hydrochloride Tablet BP 10 mg)	Review Period: 3 Years
	Product Code: G13	Effective Date: 04/03/2025

Identify any peaks corresponding to impurity-A, impurity-B and impurity-G using solution-(4) and the chromatogram supplied with cetirizine impurity standard BPCRS.Multiply the area of any peak corresponding to impurity-A by a correction factor of 0.7.

Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (3) (0.1%)

System suitability requirement:

1. The Resolution between the peaks of Cetirizine hydrochloride and cetirizine impurity-B obtained with impurity standard solution should be not less than 1.5.

Calculation:

1)Calculate the % Known impurity by using following formula,

$$= \frac{A}{B} \times \frac{W1}{20} \times \frac{1}{100} \times \frac{10}{50} \times \frac{20}{W2} \times \frac{Av}{LC} \times \frac{P}{100} \times 100 \times CF$$

2)Calculate the % Unknown impurity by using following formula,

$$= \frac{A}{B} \times \frac{W1}{20} \times \frac{1}{100} \times \frac{10}{50} \times \frac{20}{W2} \times \frac{Av}{LC} \times \frac{P}{100} \times 100$$

Were,

A = Peak area response of known / Unknown impurity obtained from the sample solution.

B = Peak area response of cetirizine Hydrochloride peak obtained with solution (2).

W1 = Equivalent weight of Cetirizine hydrochloride in mg

W2 = Weight of sample in mg

Av = Average weight of sample in mg

P = % Purity of Cetirizine Hydrochloride working standard on as is basis.

CF = Correction Factor (For impurity A = 0.7)

	Prepared by	Checked by	Approved by
Designation	Executive-QC	Sr. Executive-QC	Manager-QC
Signature			
Date	04/03/2025	04/03/2025	04/03/2025
Department: Quality Control		Date of Issue: 04/03/2025	

Total impurities = Sum of all known impurities & unknown impurities

SECTION – XII

ASSAY (By HPLC)

Refer to ASSAY AND CONTENT UNIFORMITY (SECTION- IX)

SECTION-XIII

MICROBIOLOGICAL LIMITS

Refer to SOP No. QCMB 006.

HISTORY

S. No.	Revision Number	Reason for Revision
1	Revision No.: 00	New STP No: FPSTP: G13
2	Revision No.: 01	Periodic Revision
3	Revision No.: 02	Revision reference to the change control CC/24/034.
4	Revision No.: 03	Revision reference to the change control CC/24/087
5	Revision No.: 04	Revision reference to the change control CC/25/051

END OF DOCUMENT